{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:45:23Z","timestamp":1768977923037,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Kanagawa Prefectural Hospitals Cancer Fund"},{"name":"Kanagawa Children\u2019s Medical Center Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04860-y","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:33:24Z","timestamp":1768876404000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-transplantation gilteritinib maintenance therapy and therapeutic drug monitoring in pediatric acute myeloid leukemia with FLT3\u2013internal tandem duplication"],"prefix":"10.1007","volume":"96","author":[{"given":"Masakatsu","family":"Yanagimachi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiko","family":"Iwano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Keino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Kimizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kurita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yokosuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamanoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuminori","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"12","key":"4860_CR1","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u201377","journal-title":"Blood"},{"issue":"15","key":"4860_CR2","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1200\/JCO.23.02474","volume":"42","author":"MJ Levis","year":"2024","unstructured":"Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M et al (2024) Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3. J Clin Oncol 42(15):1766\u201375","journal-title":"J Clin Oncol"},{"issue":"5","key":"4860_CR3","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41409-020-01153-1","volume":"56","author":"RT Maziarz","year":"2021","unstructured":"Maziarz RT, Levis M, Patnaik MM, Scott BL, Mohan SR, Deol A et al (2021) Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant 56(5):1180\u20139","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"4860_CR4","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21(9):1201\u201312","journal-title":"Lancet Oncol"},{"issue":"10","key":"4860_CR5","doi-asserted-by":"publisher","first-page":"3235","DOI":"10.1111\/cas.13749","volume":"109","author":"K Usuki","year":"2018","unstructured":"Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S et al (2018) Clinical profile of gilteritinib in Japanese patients with relapsed\/refractory acute myeloid leukemia: an open-label phase 1 study. Cancer Sci 109(10):3235\u201344","journal-title":"Cancer Sci"},{"issue":"10","key":"4860_CR6","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40262-020-00888-w","volume":"59","author":"AJ James","year":"2020","unstructured":"James AJ, Smith CC, Litzow M, Perl AE, Altman JK, Shepard D et al (2020) Pharmacokinetic profile of gilteritinib: a novel FLT-3 tyrosine kinase inhibitor. Clin Pharmacokinet 59(10):1273\u20131290","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"4860_CR7","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/s41375-024-02382-9","volume":"38","author":"J Wang","year":"2024","unstructured":"Wang J, Jiang B, Li J, Liu L, Du X, Jiang H et al (2024) Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed\/refractory FLT3-mutated acute myeloid leukemia. Leukemia 38(11):2410\u20132418","journal-title":"Leukemia"},{"issue":"23","key":"4860_CR8","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1182\/bloodadvances.2021005164","volume":"5","author":"D McCall","year":"2021","unstructured":"McCall D, Roth M, Mahadeo KM, Toepfer L, Nunez C, Short NJ et al (2021) Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia. Blood Adv 5(23):5215\u20139","journal-title":"Blood Adv"},{"key":"4860_CR9","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3389\/fped.2017.00248","volume":"5","author":"AN Sexauer","year":"2017","unstructured":"Sexauer AN, Tasian SK (2017) Targeting FLT3 signaling in childhood acute myeloid leukemia. Front Pediatr 5:248","journal-title":"Front Pediatr"},{"issue":"5","key":"4860_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1182\/bloodadvances.2022008991","volume":"7","author":"T Terao","year":"2023","unstructured":"Terao T, Matsuoka KI, Ueda H, Matsumura A, Matsubara C, Kondo K et al (2023) Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R\/R FLT3mut AML. Blood Adv 7(5):681\u20136","journal-title":"Blood Adv"},{"key":"4860_CR11","unstructured":"FDA (2017) Gilteritinib for Treatment of Pediatric Patients with FLT3\/ITD AML. https:\/\/www.fda.gov\/media\/106162\/download"},{"issue":"5","key":"4860_CR12","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1007\/s12185-013-1429-2","volume":"98","author":"D Tomizawa","year":"2013","unstructured":"Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T et al (2013) Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese pediatric Leukemia\/Lymphoma study group. Int J Hematol 98(5):578\u2013588","journal-title":"Int J Hematol"},{"key":"4860_CR13","doi-asserted-by":"crossref","unstructured":"Negotei C, Colita A, Mitu I, Lupu AR, Lapadat ME, Popovici CE et al (2023) A review of FLT3 kinase inhibitors in AML. J Clin Med 12(20):6429","DOI":"10.3390\/jcm12206429"},{"issue":"8","key":"4860_CR14","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","volume":"18","author":"AE Perl","year":"2017","unstructured":"Perl AE, Altman JK, Cortes J, Smith C, Litzow M, Baer MR et al (2017) Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1\u20132 study. Lancet Oncol 18(8):1061\u201375","journal-title":"Lancet Oncol"},{"issue":"11","key":"4860_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29216","volume":"68","author":"T Abematsu","year":"2021","unstructured":"Abematsu T, Nishikawa T, Shiba N, Iijima-Yamashita Y, Inaba Y, Takahashi Y et al (2021) Pediatric acute myeloid leukemia co-expressing FLT3\/ITD and NUP98\/NSD1 treated with gilteritinib plus allogenic peripheral blood stem cell transplantation: a case report. Pediatr Blood Cancer 68(11):e29216","journal-title":"Pediatr Blood Cancer"},{"key":"4860_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1286241","volume":"10","author":"KJ Leger","year":"2023","unstructured":"Leger KJ, Robison N, Narayan HK, Smith AM, Tsega T, Chung J et al (2023) Rationale and design of the Children\u2019s Oncology Group study AAML1831 integrated cardiac substudies in pediatric acute myeloid leukemia therapy. Front Cardiovasc Med 10:1286241","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"4860_CR17","first-page":"265","volume":"29","author":"AE Perl","year":"2023","unstructured":"Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E et al (2023) Outcomes in patients with FLT3-Mutated Relapsed\/ refractory acute myelogenous leukemia who underwent transplantation in the phase 3 ADMIRAL trial of gilteritinib versus salvage chemotherapy. Transpl Cell Ther 29(4):265 e1- e10","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"4860_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30108","volume":"70","author":"K Tamefusa","year":"2023","unstructured":"Tamefusa K, Ishida H, Kanamitsu K, Ochi M, Fujiwara K, Tatebe Y et al (2023) Posttransplant gilteritinib maintenance therapy for pediatric acute myeloid leukemia with myelodysplasia-related changes with FLT3-internal tandem duplication. Pediatr Blood Cancer 70(4):e30108","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"4860_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30185","volume":"70","author":"K Tasaka","year":"2023","unstructured":"Tasaka K, Kato I, Takeshita S, Yoshioka Y, Usami A, Uchihara Y et al (2023) Second relapse of FLT3-ITD-positive acute myeloid leukemia after discontinuation of 3-year post-transplant maintenance therapy with gilteritinib. Pediatr Blood Cancer 70(5):e30185","journal-title":"Pediatr Blood Cancer"},{"key":"4860_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1285346","volume":"13","author":"F Ata","year":"2023","unstructured":"Ata F, Benkhadra M, Ghasoub R, Fernyhough LJ, Omar NE, Nashwan AJ et al (2023) Tyrosine kinase inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials. Front Oncol 13:1285346","journal-title":"Front Oncol"},{"issue":"4","key":"4860_CR21","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1002\/cpt.3002","volume":"114","author":"N Jamaladdin","year":"2023","unstructured":"Jamaladdin N, Sigaud R, Kocher D, Kolodziejczak AS, Nonnenbroich LF, Ecker J et al (2023) Key pharmacokinetic parameters of 74 pediatric anticancer drugs providing assistance in preclinical studies. Clin Pharmacol Ther 114(4):904\u201313","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04860-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04860-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:20:44Z","timestamp":1768922444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04860-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4860"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04860-y","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}